Jump to content

Drilldown: Medicines

Choose a table:


Medicines > generic : 2-FMA or None & onset: Amyloid PET clearance within months; cognitive benefit over 18 months

Use the filters below to narrow your results.

generic: (Click arrow to add another value)
brand:
Kisunla (1)
classes:
Anti-amyloid beta (Aβ) monoclonal antibody (1) · targets pyroglutamated Aβ in plaques (1)
mechanism:
None (1)
uses:
Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024 (1)
starting dose:
700 mg IV q4w × 3 doses, then 1400 mg IV q4w; may discontinue when amyloid PET shows clearance (1)
preparations:
350 mg/20 mL vial for IV infusion (1)
fda max:
1400 mg q4w (1)
routes:
IV infusion every 4 weeks (1)
onset: (Click arrow to add another value)
duration:
Treatment can be discontinued upon achieving amyloid clearance (1)
halflife:
~12.1 days (1)
bioavailability:
100% (IV) (1)
pregnancy:
Limited data (1)
legal:
Rx; ARIA monitoring required (1)

Showing below up to 1 result in range #1 to #1.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"